Serena De Vita
Vice President, Global Franchise Head & Clinical Strategy Head, Late Development Oncology, Cell Therapy, ORD AstraZeneca
Serena De Vita is VP, Global Franchise Head and Global Clinical Strategy Head, Late Development Oncology, Cell Therapy at AstraZeneca, where she leads global clinical strategy and late-stage development in oncology cell therapies. With over a decade of experience across early and late-stage clinical development and a strong academic foundation in pediatric and hematologic oncology research, she brings deep expertise in translational oncology, hematologic malignancies, and global program oversight. Her career has spanned strategy development, cross-functional leadership, and the advancement of innovative therapies from early studies through to registrational programs.
Seminars
- Highlighting evolving modality innovations and industry shifts to demonstrate how rapid scientific and technological progress is enhancing treatment accessibility and reshaping the cell therapy landscape
- Aligning clinical development, scalability and patient access strategies to accelerate commercialization pathways across advanced cell therapy modalities
- Discussing post-approval reimbursement policies and strategies to ensure long-term commercial success
- Predicting cell therapy evolution through 2026 and beyond to provide strategic and commercial foresight
